Abbott Laboratories (ABT)
Abbott (ABT) Q4 Earnings Meet Estimates
Abbott (ABT) came out with quarterly earnings of $1.34 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.19 per share a year ago.
Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates
Abbott Laboratories posts total worldwide sales of $10.97 billion for the quarter ended Dec. 31, missing Wall Street estimates of $11.03 billion.
Abbott forecasts in line annual profit on medical device sales
Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated medtech-related procedures to boost demand for its devices, including glucose-monitoring products.
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
When most of us think of investing in stocks, we think of the potential gains -- or unfortunately, in some cases, losses -- that might follow. A particular stock will rise or fall, and we'll benefit or lose.
Abbott Stock Ahead of Q4 Earnings Results: Smart Buy or Risky Move?
Abbott's Diagnostics arm is expected to have been driven by the widespread adoption of its top-tier systems and high testing demand in the fourth quarter.
Unlocking Q4 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of Abbott (ABT) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Abbott Stock Trades at a Discounted P/B Value: To Buy or Not to Buy?
ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics.
Abbott Laboratories Q4 2024 Earnings Preview
Abbott Laboratories will report earnings pre-market on January 22, with an earnings consensus of $1.04 per share. Abbott continues to execute growth businesses with excellent marketing and distribution, allowing them to scale faster and farther than competitors. On the basis of favorable trends, mitigated risks, and earnings expectations, I maintain my buy rating at a price target of $133.90.
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Abbott (ABT) closed at $113.04, marking a -0.69% move from the previous day.
Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
Here is how Abbott (ABT) and Acurx Pharmaceuticals, Inc. (ACXP) have performed compared to their sector so far this year.
